The Flt3-inhibitor quizartinib augments apoptosis and promotes maladaptive remodeling after myocardial infarction in mice
-
Published:2023-11-09
Issue:
Volume:
Page:
-
ISSN:1360-8185
-
Container-title:Apoptosis
-
language:en
-
Short-container-title:Apoptosis
Author:
Monogiou Belik Daria,Bernasconi Riccardo,Xu Lifen,Della Verde Giacomo,Lorenz Vera,Grüterich Vivienne,Balzarolo Melania,Mochizuki Michika,Pfister Otmar,Kuster Gabriela M.
Abstract
Abstract
Background
Tyrosine kinase inhibitors (TKIs) targeting fms-like tyrosine kinase 3 (Flt3) such as quizartinib were specifically designed for acute myeloid leukemia treatment, but also multi-targeting TKIs applied to solid tumor patients inhibit Flt3. Flt3 is expressed in the heart and its activation is cytoprotective in myocardial infarction (MI) in mice.
Objectives
We sought to test whether Flt3-targeting TKI treatment aggravates cardiac injury after MI.
Methods and results
Compared to vehicle, quizartinib (10 mg/kg/day, gavage) did not alter cardiac dimensions or function in healthy mice after four weeks of therapy. Pretreated mice were randomly assigned to MI or sham surgery while receiving quizartinib or vehicle for one more week. Quizartinib did not aggravate the decline in ejection fraction, but significantly enhanced ventricular dilatation one week after infarction. In addition, apoptotic cell death was significantly increased in the myocardium of quizartinib-treated compared to vehicle-treated mice. In vitro, quizartinib dose-dependently decreased cell viability in neonatal rat ventricular myocytes and in H9c2 cells, and increased apoptosis as assessed in the latter. Together with H2O2, quizartinib potentiated the phosphorylation of the pro-apoptotic mitogen activated protein kinase p38 and augmented H2O2-induced cell death and apoptosis beyond additive degree. Pretreatment with a p38 inhibitor abolished apoptosis under quizartinib and H2O2.
Conclusion
Quizartinib potentiates apoptosis and promotes maladaptive remodeling after MI in mice at least in part via a p38-dependent mechanism. These findings are consistent with the multi-hit hypothesis of cardiotoxicity and make cardiac monitoring in patients with ischemic heart disease under Flt3- or multi-targeting TKIs advisable.
Funder
University of Basel
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Biochemistry (medical),Cell Biology,Clinical Biochemistry,Pharmaceutical Science,Pharmacology
Reference43 articles.
1. Ayach BB, Yoshimitsu M, Dawood F, Sun M, Arab S, Chen M, Higuchi K, Siatskas C, Lee P, Lim H, Zhang J, Cukerman E, Stanford WL, Medin JA, Liu PP (2006) Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after Myocardial Infarction. Proc Natl Acad Sci U S A 103:2304–2309. https://doi.org/10.1073/pnas.0510997103 2. Chaar M, Kamta J, Ait-Oudhia S (2018) Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. Onco Targets Ther 11:6227–6237. https://doi.org/10.2147/OTT.S170138 3. Chen MH, Kerkela R, Force T (2008) Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118:84–95. https://doi.org/10.1161/CIRCULATIONAHA.108.776831 4. Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, Reddy AK, Coombes KR, Daher IN, Pati S, Patel SS, Pocius JS, Taffet GE, Buja LM, Entman ML, Khakoo AY (2010) Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest 120:472–484. https://doi.org/10.1172/JCI39434 5. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M (2013) Phase I study of quizartinib administered daily to patients with relapsed or refractory acute Myeloid Leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 31:3681–3687. https://doi.org/10.1200/JCO.2013.48.8783
|
|